Article Information
History
- November 6, 2020.
Article Versions
- You are currently viewing Version 1 of this article (November 6, 2020 - 03:00).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Jack Gisby*,1,
- Candice L. Clarke*,1,2,
- Nicholas Medjeral-Thomas*,1,2,
- Talat H. Malik1,
- Artemis Papadaki1,
- Paige M. Mortimer1,
- Norzawani B. Buang1,
- Shanice Lewis1,
- Marie Pereira1,
- Frederic Toulza1,
- Ester Fagnano1,
- Marie-Anne Mawhin1,
- Emma E. Dutton1,
- Lunnathaya Tapeng1,
- Paul Kirk3,
- Jacques Behmoaras1,
- Eleanor Sandhu1,2,
- Stephen P. McAdoo1,2,
- Maria F. Prendecki1,2,
- Matthew C. Pickering1,
- Marina Botto1,
- Michelle Willicombe*,1,2,
- David C. Thomas*,1,2 and
- James E. Peters*,1,4,#
- 1Centre for Inflammatory Disease, Dept of Immunology and Inflammation, Imperial College London
- 2Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
- 3MRC Biostatistics Unit, Forvie Way, University of Cambridge
- 4Health Data Research UK, London, UK
- ↵#Correspondence to: James E. Peters. Email: j.peters{at}imperial.ac.uk
↵* equal contributions
Posted November 06, 2020.
Longitudinal proteomic profiling of high-risk patients with COVID-19 reveals markers of severity and predictors of fatal disease
